MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
A phase 2 trial of MIT-001 plus CCRT in head and neck squamous cell carcinoma, run by MitoImmune Therapeutics, active and no longer recruiting.
Overview
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients is a phase 2 interventional study registered as NCT04651634 by MitoImmune Therapeutics, with 60 participants enrolled, started 2021-06-21 and due to reach its primary completion in 2025-12-31. Interventions recorded: MIT-001 plus CCRT.
Similar pages
not linked directly; found by shared links- TrialFID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialTo Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Study of DM005 in Patients With Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialEfficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialClinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
Shares Head and neck squamous cell carcinoma and the tag pipeline.